Healthcare
CytoDyn Inc.(CYDY)
Live Price
Offline$0.27
+0.00% today
1Y Change
-15.65%
Window
Jun 26, 2025 โ Jun 24, 2026
- Market Cap
- $440.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +103.6%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 26, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CytoDyn Inc. (CYDY) is a Healthcare stock with a market cap of $440.00M and listed on OTC. The stock last traded around $0.27 and down 15.7% across the available one-year price window (Jun 26, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +103.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +103.6%, free cash flow +20.2% with operating margin 355.6% and ROIC 104.3%. Stock Foundry combines CYDY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Above sector median
+355.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 29, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +103.6%, while operating margin sits near 355.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 29, 2026 | โ | -0.1% | +3.2% | -3.2% |
2026 Apr 14, 2026 | โ | +1.5% | +12.5% | +4.2% |
2026 Jan 9, 2026 | +80.0% | -0.1% | -4.4% | -11.5% |
Benchmark Edge
CYDY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CYDY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CYDY Max Drawdown
-39.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CYDY and SPY.
Company Overview
CytoDyn Inc.
OTC
CytoDyn Inc. is a biotechnology firm dedicated to advancing therapies for challenging medical conditions. This dynamic company focuses primarily on developing treatments for HIV/AIDS using its leading product candidate, a monoclonal antibody called leronlimab. CytoDyn seeks to address and improve the lives of patients dealing with these conditions by leveraging novel technologies to create therapies that are both effective and accessible. With a research-driven approach, CytoDyn is also investigating leronlimab for its potential application in other therapeutic areas such as cancer, inflammatory conditions, and certain types of autoimmune diseases. The work conducted by CytoDyn is critical in the biotechnology sector, as it addresses significant unmet medical needs, potentially altering the landscape of treatment protocols. By pushing the frontier of medical research, CytoDyn Inc. holds a vital role in the pharmaceutical and biotech marketplaces, contributing to groundbreaking advancements in healthcare solutions.
- Leadership
- Dr. Jacob P. Lalezari M.D.
- Employees
- 13
- Street Address
- 1111 Main Street, Suite 660
- Mailing
- Vancouver, WA, 98660
- Region
- Vancouver, WA, United States
- Last Updated
- May 10, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +103.6%
- Free Cash Flow
- +20.2%
Profitability
- Gross Margin
- 0.3%
- Operating Margin
- 355.6%
- Net Margin
- 655.7%
- ROE
- 37.0%
- ROIC
- 104.3%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.